Skip to content

All updates

19 NovThu
30 OctFri
  1. Europe PMC: new psychedelic research papers55

    Psilocybin with psychological support for anhedonia in treatment-resistant depression: a randomised controlled pilot trial

    A randomised, double-blind, placebo-controlled pilot trial in 20 participants with treatment-resistant major depressive disorder found no statistically significant between-group difference in anhedonia at the primary week 1 endpoint, with a DARS change difference of 11.2 (95% CI, -1.0 to 23.3; p = 0.073) for psilocybin 25 mg versus 1 mg, both given with psychological support.

28 OctWed
  1. OPEN Foundation62

    OPEN Foundation reviews study on how psilocybin aligns brain activity with sensory context

    OPEN Foundation summarises a study by Stoliker and colleagues, described as the largest single-site psychedelic neuroimaging study to date, in which 62 healthy adults aged 18 to 55 with no previous meaningful psychedelic experience received a single 19 mg oral dose of psilocybin and underwent fMRI and EEG recordings across rest, guided meditation, music listening and movie viewing.

6 SepSun
  1. Europe PMC: new psychedelic research papers60

    Systematic review examines the effect of psychedelics on associative learning

    A systematic review of 62 studies, only 2 in humans, reports that psychedelic administration appears to enhance associative learning in animals across conditioning paradigms, though findings were not consistent. The authors write that direct evidence of enhanced associative learning in humans remains limited, while human studies show altered cognitive flexibility and learning-related processes.

    Why it matters: The review separates animal evidence of enhanced associative learning from the limited human data, a distinction that matters for claims about the post-acute window used in psychedelic-assisted psychotherapy.